1. Is CMV DNAemia an early marker of CMV colitis in patients with active ulcerative colitis?
- Author
-
Melotti L, Rinaldi M, Salice M, Dussias NK, Vanigli N, Calabrese C, Scaioli E, Gabrielli L, Lazzarotto T, Rosini F, Viale P, Gionchetti P, Giannella M, and Rizzello F
- Subjects
- Humans, Female, Male, Adult, Retrospective Studies, Middle Aged, Risk Factors, Prognosis, Aged, Colectomy, Biomarkers blood, Colitis virology, Colitis diagnosis, Cytomegalovirus Infections virology, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections complications, Colitis, Ulcerative virology, Colitis, Ulcerative complications, Cytomegalovirus genetics, Cytomegalovirus isolation & purification, DNA, Viral genetics, DNA, Viral blood
- Abstract
Cytomegalovirus (CMV) colitis is a serious concern worsening the prognosis of patients with ulcerative colitis (UC). We aimed to assess risk factors and prognostic impact of CMV colitis in patients with moderate-to-severe UC flare. We conducted a retrospective, observational, single-center study. Consecutive adult patients hospitalized for moderate-to-severe UC from January 2020 to June 2023 were included. The primary endpoint was a diagnosis of CMV-colitis according to immunohistochemistry on tissue biopsies. The secondary endpoint was the need for colectomy within 30 days. Overall, 135 patients were included. CMV colitis was diagnosed in n = 37 (27.4%): n = 19 (51.4%) endoscopically, the remaining on surgical specimens. Of them, n = 23 (62.2%) had positive CMV-DNAemia with a median value of 1,008 cp/mL (interquartile range 318-2,980). Differences between the two groups (CMV colitis vs non-CMV) included age (60 vs 41 years, P = 0.004), Charlson Comorbidity Index (1 vs 0, P = 0.003), steroid refractoriness (86.5% vs 62.2%, P = 0.007), and positive CMV-DNAemia (62.2% vs 10.1%, P < 0.001). At multivariable analysis, steroid-refractory disease, Charlson Comorbidity Index, and CMV-DNAemia were associated with CMV colitis. Overall, n = 54 (39.7%) patients underwent colectomy, and this was significantly more common in patients with CMV colitis vs non-CMV group (54.1% vs 34.4%, P = 0.049). Kaplan-Meier showed that antiviral therapy seems to have a relevant impact on colectomy ( P < 0.001). CMV-DNA blood detection is independently associated with CMV-positive refractory UC. Since CMV colitis may increase the risk of colectomy and antiviral treatment seems to reduce such risk, prospective studies are needed to confirm the role of CMV-DNA blood detection to early diagnose CMV colitis., Importance: Cytomegalovirus (CMV) colonic reactivation worsens the prognosis of patients with active ulcerative colitis. Blood CMV-DNA reactivation is strongly associated with CMV colitis. Prompt diagnosis and treatment of CMV colitis can avoid surgery in most cases., Competing Interests: P.G. received honoraria from Janssen, Abbvie, Pfizer, Celgene, Takeda, Ferring, MSD, Amgen, and Alfa-Sigma, and he participated in a company sponsored speaker's bureau of Abbvie, Janssen, Takeda, FGerring, MSD, Sofar, and Chiesi. F.R. received honoraria from Janssen, Abbvie, Pfizer, Takeda, Ferring, and MSD, and he participated in a company sponsored speaker's bureau of Abbvie, Jansen, Takeda, Ferring, MSD, Sofar, and Chiesi. The other authors have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF